rhTPO is a full-length, glycosylated TPO.12, 13, 14 It was approved in China in 2010 as a second-line treatment in adult ITP patients at a fixed dose of 300 U/kg/day for up to 14 days.15 The gene discussed is TPO; the disease is autoimmune thrombocytopenic purpura.